From the outset, the company combined rigorous asset selection with the clinical development capabilities needed to advance programmes with speed and excellence. CX11 is advancing toward pivotal global Phase 3 development for weight management following positive clinical results in the United States and China. Notably, more than 1,500 participants have now been studied across the CX11 clinical programme without an identified hepatic safety signal. They combine distinct strengths, whether in discovery, regional clinical development, global trial execution, or regulatory strategy, while maintaining clarity about each partner’s role. Bo Liang, MD, PhD, is chief medical officer at CORXEL and leads global clinical development of metabolic therapies toward regulatory approval.